Dosage regimen for short-lived radioisotope
AssigneeAdvanCell Pty Limited
InventorsSimon PUTTICK, Andrew ADAMOVICH, Stephen ROSE, Thomas KRYZA, Feifei LIU
Life of this patent
Estimating the term…
Abstract
There is provided a method for treating cancer in a human subject in need of treatment thereof, comprising administering to the human subject a course of treatment of an effective amount of a radiopharmaceutical comprising a therapeutic radioisotope having a half-life of less than about 24 hours, wherein at least part of the course of treatment comprises two or more separately dosed administrations of the radiopharmaceutical, each separate dose of radiopharmaceutical being independently administered at a dosage interval of about or less than about 4 weeks.
Claims30
A method of treating a human subject with metastatic prostate cancer with bone metastases comprising:
- administering to the human subject a therapeutically effective amount of a radiopharmaceutical therapy composition comprising a prostate-specific membrane antigen (PSMA) targeting ligand having 212Pb chelated thereto, wherein the radiopharmaceutical therapy composition is administered to the human subject in at least two treatment cycles separated by an interval of 7 to 14 days and at an activity per dose of between about 60 MBq to 500 MBq and wherein the metastatic prostate cancer with bone metastases is treated.
A method of treating advanced prostate cancer in a human subject in need thereof comprising:
- intravenously administering to the human subject a therapeutically effective amount of a radiopharmaceutical comprising a prostate-specific membrane antigen (PSMA) targeting ligand chelated to 212Pb;
- wherein the human subject has at least one metastatic lesion detected by computed tomography, magnetic resonance imaging, bone scintigraphy, or any combination thereof;
- wherein the therapeutically effective amount of the radiopharmaceutical has an activity per dose of about 1 MBq to about 600 MBq and is administered to the human subject in at least two treatment cycles separated by an interval of one to four weeks;
- wherein the advanced prostate cancer is treated.
A method of inhibiting the progression of metastatic prostate cancer in a human subject with a bone lesion comprising:
- intravenously administering to the human subject a therapeutically effective amount of a radiopharmaceutical therapy composition comprising a prostate-specific membrane antigen (PSMA) targeting ligand having 212Pb chelated thereto, wherein the radiopharmaceutical therapy composition is administered to the human subject in at least two treatment cycles separated by an interval of 7 to 14 days and at an activity per dose of between about 60 MBq to 500 MBq and wherein the metastatic prostate is treated.
A method of treating a human subject with metastatic prostate cancer with bone metastases comprising:
- administering to the human subject a therapeutically effective amount of a radiopharmaceutical therapy composition comprising a prostate-specific membrane antigen (PSMA) targeting ligand having 212Pb chelated thereto,
- wherein the human subject exhibits a criteria selected from histologically confirmed adenocarcinoma of the prostate, cytologically confirmed adenocarcinoma of the prostate, demonstrated PSMA-positive disease as determined by PSMA-targeted positron emission tomography (PET) imaging, wherein at least one metastatic lesion exhibits radiotracer uptake greater than uptake in normal liver tissue, radiographically documented metastatic disease comprising at least one bone metastatic lesion, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2;
- wherein the radiopharmaceutical therapy composition is administered to the human subject in at least two treatment cycles separated by an interval of 7 to 14 days and at an activity per dose of between about 60 MBq to 500 MBq;
- and
- wherein the metastatic prostate cancer with bone metastases is treated, wherein treatment is progression free survival for at least 6 months.
Dependencies are inferred from the claim text.